Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

33.22 -0.97 (-2.83%)
Streaming Delayed Price Updated: 1:25 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Biotech Playbook 2021: No Help From Small Caps In Q4
Mid-cap stock picks have done better today but are way off their 2021 highs. Cryoport and Veracyte are still up and look better technically. Quidel was up 5.48% today on Omicron concerns globally but... 
Via Talk Markets
Adobe Earnings Strangle Trade
Adobe announces earnings this week, and we plan on using an options strategy called a 
Via Talk Markets
CRISPR Therapeutics Is One of Today’s Best Biotech Value Investments
Don't let the downtrend in CRSP stock fool you; the company is still making headway in advancing potentially life-changing therapeutics. 
Via InvestorPlace
Why CRISPR Therapeutics Stock Sank 12.5% in November
The gene-editing specialist's share price is now down roughly 54% in 2021. 
Via The Motley Fool
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
Biotech Stocks are Due for a Rally
There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
Via Talk Markets
Do CRISPR Therapeutics and Intellia Face a Big Safety Risk?
CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations. 
Via The Motley Fool
Better Buy: Vertex Pharmaceuticals vs. CRISPR
The companies are collaborating on a potential blockbuster. 
Via The Motley Fool
Looking for Growth in Small and Mid Cap Life Science Stocks
2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
Via Talk Markets
Being First Is Not Enough For Crispr Therapeutics
CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. 
Via InvestorPlace
Why CRISPR Therapeutics Stock Fell 18.4% in October
The gene-editing specialist's stock is now down roughly 37% year to date. 
Via The Motley Fool
Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics
Vertex plans to develop gene-editing therapies with Mammoth Biosciences. 
Via The Motley Fool
3 Things About CRISPR Therapeutics That Smart Investors Know
The company's value isn't reflected in typical performance metrics. 
Via The Motley Fool
2 Gene-Editing Stocks to Have on Your Radar Right Now
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies. 
Via The Motley Fool
2 Top Healthcare Stocks That Could Be Bought Out in 2022
These two novel-drug makers could be top takeover targets next year. 
Via The Motley Fool
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021
Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
Via Benzinga
If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today
The returns haven't been half bad, to say the least. 
Via The Motley Fool
Crispr: A Fallen Angel In Gene Editing
As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
Via Talk Markets
Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review
It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields. 
Via Investor's Business Daily
Exposures Fossil Fuels
BZ Chart Of The Day: Is Crisper Therapeutics About To Rally?
Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) may be form... 
Via Benzinga
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc... 
Via Benzinga
Exposures COVID-19
CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today
Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. 
Via InvestorPlace
50 Biggest Movers From Yesterday
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target... 
Via Benzinga
Why CRISPR Therapeutics Stock Is Sinking Today
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate. 
Via The Motley Fool
Why CRISPR Therapeutics Stock Is Tumbling Today
CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
20 Stocks Moving in Wednesday's Pre-Market Session
Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, Inc. (NASDAQ: JSPR) rose 38% to $9.95 in pre-... 
Via Benzinga
Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall?
Crispr is planning to begin a registrational test in the first quarter of 2022. 
Via Investor's Business Daily
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.